最新临床试验：阿昔替尼和尼伐单抗治疗不能切除或转移的TFE/易位肾细胞癌

这是经美国国家癌症研究所批准的一项多中心随机对照II期临床试验，目的是研究阿昔替尼和尼伐单抗在治疗TFE/易位肾细胞癌患者中的作用，这些TFE/易位肾细胞癌不能通过手术切除或已扩散到身体其他部位。阿昔替尼可以通过阻断细胞生长所需的一些酶来阻止肿瘤细胞的生长。用单克隆抗体如尼伐单抗进行免疫治疗，可能有助于人体免疫系统攻击癌症，并可能干扰肿瘤细胞的生长和扩散能力。与标准疗法相比，给予阿昔替尼和尼洛单抗治疗TFE/易位肾细胞癌患者的疗效可能更好，包括手术、化疗或其它免疫治疗。

该临床试验正在全美213家医院进行开展。

This phase II trial studies how well axitinib and nivolumab works in treating patients with TFE / translocation renal cell carcinoma that cannot be removed by surgery or has spread to other places in the body. Axitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving axitinib and nivolumab may work better in treating patients with TFE / translocation renal cell carcinoma compared to standard treatment, including surgery, chemotherapy, or immunotherapy.